General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Investor relations contacts

For all other queries:

Main Switchboard
Switzerland
+41 61 324 11 11

US switchboard

+1 862 778 21 00

Email address:
Stephen Rubino
Vice President, Investor Relations 
+1 862 778 83 01
Susan Donofrio +1 862 778 92 57
Mailing address:

Novartis Corporation
Investor Relations
One South Ridgedale Avenue
East Hanover, NJ 07936

Stock chart
Q3 Results 2013

On Thursday, April 24, Novartis will announce its results for the first quarter of 2014